Track topics on Twitter Track topics that are important to you
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates use a common patent-protected technology platform to deliver genes that produce medically beneficial proteins directly at the site of disease. TNFerade™ represents a novel approach to treating cancer in combination with radiation and/or chemotherapy by introducing tumor necrosis factor-alpha (TNF-alpha), a potent anti-cancer protein, directly into tumors. Pancreatic cancer is the lead indication for TNFerade™. We are conducting a 330-patient randomized, controlled Phase II/III clinical trial designed to assess the safety and clinical benefit of using TNFerade™ in combination with standard of care treatment in patients with locally advanced pancreatic cancer. Phase II trials in rectal cancer and melanoma are also ongoing. AdPEDF is being developed for patients with wet age-related macular degeneration (AMD) to determine whether pigment epithelium-derived factor (PEDF) prevents vision loss in this leading cause of blindness in people over the age of 50. We have completed a Phase I clinical trial of PEDF in patients with severe AMD. Data from this trial demonstrated that PEDF was generally well tolerated with no dose limiting toxicities. Expanded clinical testing of PEDF in AMD patients with less severe disease is ongoing. TherAtoh Atonal Therapy is a product concept to restore hearing or balance function through the regeneration of critical cells of the inner ear. Hearing and Balance require specialized cells of the inner ear called sensory hair cells. During embryonic development a gene termed atonal (ATOH) induces the generation of these cells. GenVec has shown preclinically that the production of the ATOH protein results in the formation of new inner ear sensory hair cells, and the restoration of hearing and balance function. TherAtoh is an adenovector product delivering the human atonal gene (Hath1) to trigger the production of therapeutic proteins by cells in the inner ear. We also are using GenVec's proprietary adenovector technology to develop vaccines for infectious diseases. Worldwide HIV vaccine in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) Malaria vaccine in collaboration with U.S. Navy and PATH's Malaria Vaccine Initiative Foot and Mouth Disease antiviral and vaccine program in collaboration with the United States Department of Agriculture/Agricultural Research Services (USDA-ARS) Seasonal and pandemic influenza vaccines in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID) GenVec, Inc. is based in Gaithersburg, Maryland. GenVec, Inc. is based in Gaithersburg, Maryland.
65 West Watkins Mill Road
United States of America
Phone: (240) 632-0740 or (877) 943-6832
Fax: (240) 632-0735
Intrexon Corp. acquired GenVec Inc. (gene delivery) for an undisclosed price.
GenVec, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investment ReportSummaryMarketline's GenVec, Inc. Mergers Acquisitions MA, Partnerships Alliances and Investments report includes ...
Pancreatic cancer gene therapy drug pulled in phase III.
Forthcoming news stories - GSK to supply free vaccines to poor Americans; GenVec shares crash after failure of late stage cancer drug trials; and Eli Lilly's plans for massive expansion in China.
GenVec Inc GNVC Financial and Strategic SWOT Analysis Review provides you an indepth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to...
Arena Pharmaceuticals and GenVec are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their earnings, risk, analyst recommendations, pr...
Top stories on January 20th, 2010: Obama healthcare reforms "on life support" after Republican victory Turning Japanese: Novartis gets approval for three drugs GenVec in hearing loss deal with Novart...
SummaryGenVec Inc GenVec focuses on the research and development of genebased medicine. It develops therapeutics and vaccines using its proprietary adenovector gene delivery platform. The company's le...
GenVec, Inc. (NASDAQ: GNVC) is a biopharmaceutical company developing novel gene-based therapeutic drugs and vaccines. Each of our gene-based therapeutic product candidates use a common patent-protect...
We have published hundreds of GenVec news stories on BioPortfolio along with dozens of GenVec Clinical Trials and PubMed Articles about GenVec for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of GenVec Companies in our database. You can also find out about relevant GenVec Drugs and Medications on this site too.
Bioinformatics is the application of computer software and hardware to the management of biological data to create useful information. Computers are used to gather, store, analyze and integrate biological and genetic information which can then be applied...